Dmitry Gavrilenko speaks at the First Forum "Compliance and Law Enforcement Practice in Pharmaceuticals"

The forum was organized by the Association of Russian Pharmaceutical Manufacturers. According to Dmitry Gavrilenko, the relevance of the topics at the forum, is obvious: legal practice in the pharmaceutical industry is one of the most difficult. Numerous legislative amendments initiated by the regulator to encourage a more responsible and transparent business, its struggle for the availability of drugs,- are the issues that the market players often perceive only as limitations - tightening rules and reducing opportunities for growth. Market actions of the world's pharmaceutical giants are often the occasion for high-profile litigation.

Representatives of industry regulators, heads of legal departments of the largest Russian and foreign companies of the pharmaceutical sector, representatives of compliance-control departments, risk management departments, internal audit, corporate management, services gathered at the Marriott Grand Hotel in Moscow to discuss the full range of issues related to building effective compliance, economic security, departments of corporate ethics and executive procedures, representatives of law firms, etc.

How the new aspects of legislation will affect the pharmaceutical business; what should be taken into account when building a development strategy in 2018; how to ensure proper quality control, avoid technological and competitive violations; what are the best ways to promote medicine, new channels of communication with medical workers today? These and many other questions were discussed by the pharma industry professionals at their first compliance meeting on November 24, 2017.

At the beginning of the plenary session of the Forum, Dmitry Gavrilenko and deputy head of the legal department of the FAS Russia Igor Antonov made a joint report containing review and analysis of the main changes in legislation and law enforcement practice in the field of antimonopoly regulation.

Dmitry Gavrilenko also talked about the latest changes related to the responsibility for violation of antitrust regulation, the importance of monitoring changes in legislation that affect the determination of the materiality of risks taken into account in the antimonopoly compliance system. He also touched upon the specifics of calculating administrative penalties for antimonopoly violations, as well as determining the circumstances that mitigate administrative liability.